Robert Martin Motz

All filings by Robert Martin Motz on record concern Acerus Pharmaceuticals Corporation. We count 8 filings; the first trade dates from 20 November 2018 and the latest from 11 May 2022.

Purchases make up the whole of the open-market record (6 purchases, €3,903). Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2022, the count stands at 4 purchases and no sales.

The median purchase comes to €500. Across 6 purchases, this insider has always bought alone, with no colleague buying within 30 days.

The newest entry dates from 11 May 2022: an open-market purchase of €332, in Acerus Pharmaceuticals Corporation. Publication is fast: at least half of the trades appear on SEDI on the same day. Until a filing is published, the market cannot know about the trade. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.